Stockscreener 앱 받기
2.54
4.15%
-0.11
Taysha Gene Therapies Inc 주식(TSHA)의 최신 뉴스
Taysha Gene Therapies’ SWOT analysis: promising Rett syndrome therapy boosts stock outlook - Investing.com Australia
Taysha Gene Therapies price target maintained at $13 by Cantor Fitzgerald - Investing.com Canada
Taysha gene therapies stock rating reiterated by Cantor Fitzgerald - Investing.com Canada
Cantor Fitzgerald Adjusts Price Target on Taysha Gene Therapies to $13 From $7, Maintains Overweight Rating - marketscreener.com
Taysha Gene Therapies (TSHA) Price Target Raised Amid High Trial Success Confidence | TSHA Stock News - GuruFocus
Needham Reiterates Buy Rating for Taysha Gene Therapies (TSHA) | - GuruFocus
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Li - GuruFocus
Signify Bio’s $15M round advances in situ protein therapeutics - BioWorld MedTech
Kalkine: Taysha Gene Therapies Grants Equity Awards to New Joiners – A Closer Look at FTSE 350 Companies' Global Peers - Kalkine Media
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule - TipRanks
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | TSHA Stock News - GuruFocus
Taysha Gene Therapies (TSHA) Grants Stock Options to New Employees | TSHA Stock News - GuruFocus
Taysha Gene Therapies Grants Stock Options to New Employees Under Inducement Plan - Nasdaq
Gene Therapy Leader Taysha Awards Massive 401K Share Options Package to Key New Executives - Stock Titan
Finance Watch: Vera Raises Debt, Taysha And Trevi Price Offering After Big Trial Wins - insights.citeline.com
Taysha Gene Therapies Stock (TSHA): Innovative Gene Therapy Focus - Value The Markets
Taysha Gene Therapies Releases TSHA-102 Clinical Program Updates - Insider Monkey
Retail Buzz Surges Around Taysha Gene Therapies After Positive Rett Syndrome Trial Data - MSN
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Purchased by ProShare Advisors LLC - Defense World
BNP Paribas Financial Markets Acquires New Shares in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Jane Street Group LLC Acquires 62,003 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies (NASDAQ:TSHA) Given New $11.00 Price Target at Canaccord Genuity Group - Defense World
Taysha reports progress in Rett syndrome gene therapy trials By Investing.com - Investing.com South Africa
Retail Buzz Surges Around Taysha Gene Therapies After Positive Rett Syndrome Trial Data By Stocktwits - Investing.com India
taysha gene therapies increases authorized shares to 700 million By Investing.com - Investing.com Nigeria
Taysha Gene Therapies (TSHA) Advances TSHA-102 Program for Rett - GuruFocus
Taysha Gene Therapies Announces Details for Oral Presentations a - GuruFocus
Taysha reports progress in Rett syndrome gene therapy trials - Investing.com Australia
Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program - The Manila Times
Taysha Gene Therapies Announces Details For Oral Presentations - marketscreener.com
Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program | TSHA Stock News - GuruFocus
Taysha Gene Therapies Announces Details for Oral - GlobeNewswire
Needham Lifts Taysha Gene Therapies (TSHA) PT to $8, Cites Positive Clinical Data - Insider Monkey
Taysha Gene Therapies’ (TSHA) Buy Rating Reaffirmed at Needham & Company LLC - Defense World
Taysha Gene Therapies (TSHA) Target Price Raised by Canaccord Ge - GuruFocus
Taysha Gene Therapies (TSHA) Price Target Raised by Canaccord | - GuruFocus
taysha gene therapies increases authorized shares to 700 million - Investing.com
Taysha Gene Therapies Approves Share Increase Amendment - TipRanks
Taysha Gene Therapies (TSHA) Price Target Raised by Canaccord | TSHA Stock News - GuruFocus
Positive Outlook for Taysha Gene Therapies: Buy Rating on Promising TSHA-102 Advancements - TipRanks
Taysha Gene Therapies (TSHA) Updates Clinical Progress in Rett S - GuruFocus
Where Taysha Gene Therapies Stands With Analysts - Benzinga
Needham Adjusts Taysha Gene Therapies Price Target to $8 From $6, Maintains Buy Rating - marketscreener.com
Taysha Gene Therapies (TSHA) Sees Increased Price Target by Needham | TSHA Stock News - GuruFocus
Needham Increases Price Target for Taysha Gene Therapies (TSHA) to $8 | TSHA Stock News - GuruFocus
Taysha Gene Therapies (TSHA) Price Target Raised by JMP on Positive Rett Syndrome Trial Data - MSN
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Stake Lessened by Deutsche Bank AG - Defense World
Bank of America Corp DE Boosts Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Cantor Fitzgerald Keeps Their Buy Rating on Taysha Gene Therapies (TSHA) - The Globe and Mail
Taysha Gene Therapies (NASDAQ:TSHA) Given New $6.00 Price Target at JMP Securities - Defense World
1.91%
1.17%
자본화:
|
볼륨(24시간):